Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease

R. Inzelberg, P. Nisipeanu, M. J. Rabey, A. D. Korczyn*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a long half‐life and can be given in a single daily dose. Seventeen patients with severe fluctuations were treated with cabergoline, seven of them for >1 year (up to 39 months). The motor status ameliorated and the percentage of “off” hours significantly decreased in the first year and did not increase significantly later during long‐term follow‐up. Cabergoline is a promising treatment for parkinsonian patients with motor fluctuations.

Original languageEnglish
Pages (from-to)604-607
Number of pages4
JournalMovement Disorders
Volume10
Issue number5
DOIs
StatePublished - Sep 1995

Keywords

  • Cabergoline
  • Dopamine agonist
  • Dyskinesias
  • Motor fluctuations
  • On‐off phenomenon
  • Parkinson's disease

Fingerprint

Dive into the research topics of 'Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease'. Together they form a unique fingerprint.

Cite this